Search
Search Results
-
Statins and prostate cancer—hype or hope? The epidemiological perspective
BackgroundMen using cholesterol-lowering statin medications have been found to have lower risks of both advanced and fatal prostate cancer in...
-
A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA)
BackgroundIn men with a rising PSA following radical prostatectomy, salvage radiation therapy (SRT) offers a second chance for cure. Hormonal therapy...
-
Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study)
BackgroundEnzalutamide is an oral androgen receptor targeted agent that has been shown to improve survival in PREVAIL trials and has been approved...
-
Androgen receptor function and targeted therapeutics across breast cancer subtypes
Despite significant progress in breast cancer (BC) therapy, it is globally the most commonly diagnosed cancer and leads to the death of over 650,000...
-
Analysis of genetic biomarkers, polymorphisms in ADME-related genes and their impact on pharmacotherapy for prostate cancer
Prostate cancer (PCa) is a non-cutaneous malignancy in males with wide variation in incidence rates across the globe. It is the second most reported...
-
Recent Advances of Iron Oxide Nanoparticles-Based Nanomedicine for Prostate Cancer (Review)
Prostate cancer (PC) is one of the commonly diagnosed cancers among men in the world. Clinical outcomes are excellent for patients with localized...
-
A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC)
BackgroundDickkopf-related protein 1 (DKK1) is a Wingless-related integrate site (Wnt) signaling modulator that is upregulated in prostate cancers...
-
-
Inhibition of USP14 enhances the sensitivity of breast cancer to enzalutamide
BackgroundAndrogen receptor (AR) is expressed in approximately 70% of breast tumors. Recent studies increasingly support AR as a potential...
-
Design issues with lutetium-177 PSMA-617 registration studies that bias the outcome of the experimental arm reflect an increasing misalignment of contemporary oncology trials with true patient benefit
In the PSMAfore randomized controlled trial patients with chemotherapy naïve castrate resistant metastasized prostate cancer (CRPC) progressing after...
-
Prostate Cancer
Prostate cancer is a highly prevalent cancer in older men. Its clinical course is extremely variable. Detection of prostate cancer has been improved...
-
Transcriptional mediators of treatment resistance in lethal prostate cancer
Metastatic castration-resistant prostate cancer is typically lethal, exhibiting intrinsic or acquired resistance to second-generation...
-
Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification
BackgroundNearly one-third of patients with prostate cancer (PCa) experience biochemical recurrence (BCR) after primary definitive treatment. BCR...
-
Suppression of bone metastatic castration-resistant prostate cancer cell growth by a suicide gene delivered by JC polyomavirus-like particles
Prostate cancer is one of the most common cancers in men. The heterogeneity and mutations exhibited by prostate cancer cells often results in the...
-
Peroxisomal β-oxidation enzyme, DECR2, regulates lipid metabolism and promotes treatment resistance in advanced prostate cancer
BackgroundPeroxisomes are central metabolic organelles that have key roles in fatty acid homoeostasis. As prostate cancer (PCa) is particularly...
-
Insight into Intratumoral Heterogeneity Through Single CTC Sequencing and CDX Analysis
Tumors contain a high degree of molecular heterogeneity which is the substrate of therapeutic resistance and is rooted both by genomic instability...
-
Metformin regulates multiple signaling pathways within castration-resistant human prostate cancer cells
BackgroundThe biguanide metformin has been shown to not only reduce circulating glucose levels but also suppress in vitro and in vivo growth of...
-
Prevalence of tumour-infiltrating CD103+ cells identifies therapeutic-sensitive prostate cancer with poor clinical outcome
BackgroundThe clinical significance and immune correlation of CD103 + cells in prostate cancer (PCa) remain explored.
MethodsIn total, 1080 patients...
-
Molecular panorama of therapy resistance in prostate cancer: a pre-clinical and bioinformatics analysis for clinical translation
Prostate cancer (PCa) is a malignant disorder of prostate gland being asymptomatic in early stages and high metastatic potential in advanced stages....
